All In MedTech

FDA Clearance Tracker · P150031-S028

Vercise Deep Brain Stimulation (DBS) System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 29, 2020 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 29, 2020

Approved

Time to decision

365 days

Received Dec 30, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P150031-S028
Device name
Vercise Deep Brain Stimulation (DBS) System
Applicant location
Valencia, CA
Received
Dec 30, 2019
Decided
Dec 29, 2020
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P150031

Device type

Device class
Class III

Every decision under product code NHL

FDA's approval statement

As written in FDA's record.

Approval for the Vercise PC and Vercise Gevia DBS Systems for expanding the indications to include bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy to reduce some of the symptoms of advanced levodopa-responsive Parkinsons disease that is not adequately controlled by medications.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.